Identification and development of new protein kinase inhibitors became these last two decades the key point for the search of new therapeutic agents because, the disorder of these enzymes in cellular environment is often the cause of pathologies as cancer and Alzheimer's disease (AD). In our laboratory, it was highlighted that N,N'-bis(5-arylidene-4-oxo-4,5-dihydrothiazolin-2-yl)aminopropylpiperazine (IC₅₀ 40 nM) presented selective inhibition towards the protein kinase DYRK1A [1,2] (dual specificity, tyrosine phosphorylation regulated kinases), enzyme suspected to have an impact on neurodegenerative diseases [3-5] and cancer [6]. To understand the mechanism of action towards DYRK1A and GSK3alpha/beta, we developed a route in 6 steps for a series of 5-arylidene-3-(arylmethyl)aminobutyl-2-thioxo-1,3-thiazolidine-4-ones. This methodology involved the construction of the 2-thioxo-1,3-thiazolidine-4-one platform under microwave irradiation from commercial bis(carboxymethyl)trithiocarbonate. The results of this multi-steps synthesis as well as the biological evaluations will be presented and discussed in this poster.

References
1. Coulibaly W-K., Paquin L., Bénie A., Bekro Y-A., Durieux E., Rucheau S., Meijer L., Le Guével R., Corlu A., Bazureau J-P., Scienta Pharm. 2012, 80, 825-836.
2. Coulibaly W-K, Paquin L., Bénie A., Bekro Y-A., Durieu E., Meijer L., Bazureau J-P. Eur. J. Med. Chem. 2012, 58, 581-590.
3. Debdab M., Carreaux F., Renault S., Meijer L., Bazureau J.-P. et al. J. Med. Chem. 2011, 54, 4172-4186.
4. Tahtouh T., Burgy G., Carreaux F., Bazureau J-P., Meijer L. et al. J. Med. Chem. 2012, 55, 9312-9330.
5. Burgy G., Limanton E., Meijer L., Carreaux F., Bazureau J-P. Eur. J. Med. Chem. 2013, 62, 728-737.
6. Ionescu A., Dufrasne F., Gelbcke M., Jabin I., Kiss R., Lamoral-Theys D. Mini-Rev. Med. Chem. 2012, 12, 1315-1329.